Spire Semiconductor Wins Contract to Develop Highly Efficient Solar Cells

Spire Corporation (Nasdaq: SPIR) today announced that its wholly owned subsidiary, Spire Semiconductor, LLC, has been awarded an 18-month, $3,706,359 program by the Department of Energy's National Renewable Energy Laboratory (NREL), consisting of $2,960,850 in government funding and a $745,509 cost share. Under the contract, Spire Semiconductor will develop next-generation manufacturing technology to produce 42% efficient III-V three junction tandem concentrator solar cells.

Edward D. Gagnon, General Manager of Spire Semiconductor, stated, “We are pleased that NREL selected Spire to participate in this highly competitive Photovoltaic (PV) Technology Incubator program, whose goal is to shorten the timeline for companies to transition prototype and pre-commercial PV technologies into pilot and full-scale manufacture. Our new growth technique has the potential for producing concentrator cells with record-level efficiencies with lower manufacturing costs and higher reliability.”

Roger G. Little, Chairman and CEO of Spire Corporation, added, “Spire has been involved in the solar energy market for over 25 years. Development of this cell will put us in an excellent position to capitalize on the growing market opportunity for custom gallium arsenide (GaAs) based solar cells for Concentrator Photovoltaic (CPV) systems. Our Spire Semiconductor facility has state-of-the-art capabilities for producing these devices. We plan to offer our new series of triple junction “Triathlon” concentrator solar cells to system integrators around the world.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.